First Washington Corp Alaunos Therapeutics, Inc. Transaction History

First Washington Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$3.95 - $5.35 $38,713 - $52,435	-9,801 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$1.61 - $3.62 $1,081 - $2,432	-672 Reduced 6.42%	9,801 $18,000
Q3 2018 Nov 13, 2018	SELL	$2.26 - $3.27 $219 - $317	-97 Reduced 0.92%	10,473 $34,000
Q1 2018 May 04, 2018	SELL	$3.46 - $5.14 $4,404 - $6,543	-1,273 Reduced 10.75%	10,570 $41,000
Q3 2017 Nov 07, 2017	BUY	$4.99 - $6.57 $59,096 - $77,808	11,843	11,843 $73,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of First Washington Corp, based on Form 13F filings with the SEC.

Stay updated on First Washington Corp with notifications on news.